News & Updates

Combining the programmed cell death ligand 1 (PDL-1) inhibitor avelumab with paclitaxel plus ramucirumab appears to be efficacious and safe in the second-line treatment of metastatic esophagogastric adenocarcinoma, as shown in the phase II nonrandomized RAP trial.

A recent study has demonstrated the extended physicochemical stability of cetuximab in opened vials and infusion bags, which can help save costs for healthcare providers.

A recent study suggests that an ultrasound-based classification of thyroid nodules as either benign or malignant can improve its diagnostic accuracy by combining it with polygenic risk scores (PRS).

Delays in postoperative radiation therapy (PORT) may lead to increased locoregional recurrence (LRR), usually occurring beyond the radiation field, among patients with Merkel cell carcinoma (MCC), as shown in a recent study.

Adding bevacizumab (B) to temozolomide (T)-based chemotherapy increases overall response rate (ORR) in children with relapsed/refractory (R/R) neuroblastoma, according to results of the three-by-two factorial, randomized controlled phase II BEACON-Neuroblastoma trial.

Recently published data from the cancer programme of the 100,000 Genomes Project, which maps out the genomic patterns of patients with different cancer types using whole-genome sequencing (WGS), have provided insights on integrating genomics into routine cancer care.

A meta-analysis and meta-regression of randomized controlled trials (RCTs) found that social media-based interventions – which are interventions from any form of online medium that enables participant interaction (eg, Facebook, Instagram, TikTok, Twitter) – may be beneficial for cancer patients.

The risk of suicide attempts among parents of children with cancer is higher during the first years following cancer diagnosis, particularly when the child is diagnosed at age 18 years or below, or with an aggressive or fatal form of cancer, a study has found.